







Figure 3.




Figure 4.

Photographs of affected toenails presented in investigator-blinded settings for objective assessments of the resin, amorolfine and terbinafine treatment arms. Labels (a) and (b) indicate outcome assessments: (a) improved and (b) ineffective. Photographs were taken before treatment (left), at 4 months (centre) and at 10 months (right).

The costs of the resin lacquer, amorolfine lacquer and terbinafine treatment were €41.6, €56.3 and €52.1 per patient, respectively, during the entire treatment period. This represented €0.15, €0.21 and €0.58, respectively, per patient per treatment day. The differences in cost were highly significant among all treatment arms, both per day and per treatment course ($P < 0.001$).

Safety and Tolerability

In the terbinafine treatment arm, no patients were excluded due to increased γ -glutamyl transferase at the 2-week laboratory control test. However, two patients experienced adverse events that resulted in treatment discontinuation (8% of patients in the terbinafine arm), and both events were deemed to be due to terbinafine treatment. One patient (4%) experienced a gastrointestinal disorder that manifested as diarrhoea, and the other patient (4%) developed a rash that was potentially related to terbinafine treatment. No patient

